by Gemma Escarré,
Spherium Biomed, specialized in developing biomedical products developed in academia and a member of CataloniaBio & HealthTech, has presented the positive results of the Phase II clinical trial of an innovative treatment for atopic dermatitis at the European Academy of Dermatology and Venerology Congress in Paris.
This is Spherium’s fourth pharmaceutical product in clinical stages and the third to pass the Phase II efficacy studies. The Cyclatop global market is in the 6 billion dollar range worldwide, with an estimated target population of 54 million people for the next decade.
According Luis Ruiz-Ávila, CEO of the biopharmaceutical company: "The next milestone is to get partners to finalize Cyclatop's development, registration and marketing around the world. We hope that the product can reach the market by 2024."